Study with Elranatamab vs Lenalidomide in Newly Diagnosed Multiple Myeloma Patients after Transplant

• Research type

  Research Study

• Full title

  A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF 06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION

• IRAS ID

  1008624

• Contact name

  Nathalie Bouxin

• Contact email

  nathalie.bardy-bouxin@pfizer.com

• Sponsor organisation

  Pfizer Inc.

• Eudract number

  2021-006052-14

• Clinicaltrials.gov Identifier

  NCT05317416

• Research summary

  The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. Participants in the study will either receive elranatamab (arm C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately six years.

• REC name

  Wales REC 2

• REC reference

  24/WA/0002

• Date of REC Opinion

  12 Feb 2024

• REC opinion

  Further Information Favourable Opinion